- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 8 Nov 21 Selected recommended Phase 2 dose (RP2D) of zotatifin for continued development for patients with certain solid tumors
- 1 Nov 21 Departure of Directors or Certain Officers
- 31 Aug 21 Changes in Registrant's Certifying Accountant
- 31 Aug 21 Entry into a Material Definitive Agreement
- 24 Aug 21 Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination
- 23 Aug 21 Other Events
- 3 Jun 21 Locust Walk Acquisition Corp. Receives Notification of Deficiency from Nasdaq
Exhibit 16.1
August 31, 2021
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Ladies and Gentlemen:
We have read eFFECTOR Therapeutics, Inc. (formerly known as Locust Walk Acquisition Corp.) statements included under Item 4.01 of its Form 8-K dated August 31, 2021. We agree with the statements concerning our Firm under Item 4.01, in which we were informed of our dismissal on August 25, 2021, following completion of the Company’s quarterly review for the period ended June 30, 2021, which consists only of the accounts of the pre-Business Combination Special Purpose Acquisition Company. We are not in a position to agree or disagree with other statements contained therein.
Very truly yours,
/s/ WithumSmith+Brown, PC
New York, New York